Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with ...
Updated: Aug 23, 2022
February 2022
Septerna emerges with $100M to spark 'second golden age' of prolific drug target GPCR with pioneer as co-founder
"Jan 27, 2022 07:00am Septerna wants to spark a second golden age in G-protein-coupled receptor drug discovery.
Better known as GPCR, the fruitful research space has led to more than 700 approved drugs over previous decades—but the two-year-old biotech believes the area is still ripe for development, and it now has $100 million to help power its efforts. The company's co-founder, GPCR pioneer and Nobel laureate Robert Lefkowitz, M.D., has 50 years of experience with the target and analogizes the search for new drugs to oil drilling around the world."